Cox regression analysis, using leave-one-out cross validation, suggested that COL19A1 gene levels above mean average (0.819) and high ALSFRS-r slope at sampling scores above mean average (≥ 1 points/month) could promote a 20% reduction in the lifespan of ALS patients (COL19A1 , HR: 2.114, CI: 1.678-2.772, P =0.019, ALSFRS-r slope at sampling, HR: 2.368, CI: 1.763-3.181, P <0.001). This evidence concerns the gene COL19A1 and amyotrophic lateral sclerosis.